Cargando…
Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer
Humoral hypercalcemia of malignancy (HHM) is caused by the oversecretion of parathyroid hormone-related peptide (PTHrP) from malignant tumors. Although any tumor may cause HHM, that induced by intrahepatic cholangiocarcinoma (ICC) or gastric cancer (GC) is rare. We report here a 74-year-old male who...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442343/ https://www.ncbi.nlm.nih.gov/pubmed/28573053 http://dx.doi.org/10.1155/2017/7012520 |
_version_ | 1783238391289085952 |
---|---|
author | Takeda, Katsushi Kimura, Ryosuke Nishigaki, Nobuhiro Sato, Shinya Okamoto, Asami Watanabe, Kumiko Yasui, Sachie |
author_facet | Takeda, Katsushi Kimura, Ryosuke Nishigaki, Nobuhiro Sato, Shinya Okamoto, Asami Watanabe, Kumiko Yasui, Sachie |
author_sort | Takeda, Katsushi |
collection | PubMed |
description | Humoral hypercalcemia of malignancy (HHM) is caused by the oversecretion of parathyroid hormone-related peptide (PTHrP) from malignant tumors. Although any tumor may cause HHM, that induced by intrahepatic cholangiocarcinoma (ICC) or gastric cancer (GC) is rare. We report here a 74-year-old male who displayed HHM with both ICC and GC and showed an elevated serum PTHrP level. Treatment of the hypercalcemia with saline, furosemide, elcatonin, and zoledronic acid corrected his serum calcium level and improved symptoms. Because treatment of ICC should precede that of GC, we chose chemotherapy with cisplatin (CDDP) and gemcitabine (GEM). Chemotherapy reduced the size of the ICC and decreased the serum PTHrP level. One year after diagnosis, the patient was alive in the face of a poor prognosis for an ICC that produced PTHrP. Immunohistochemical staining for PTHrP was positive for the ICC and negative for the GC, leading us to believe that the cause of the HHM was a PTHrP-secreting ICC. In conclusion, immunohistochemical staining for PTHrP may be useful in discovering the cause of HHM in the case of two cancers accompanied by an elevated serum PHTrP level. Chemotherapy with CDDP and GEM may be the most appropriate treatment for a PTHrP-secreting ICC. |
format | Online Article Text |
id | pubmed-5442343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-54423432017-06-01 Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer Takeda, Katsushi Kimura, Ryosuke Nishigaki, Nobuhiro Sato, Shinya Okamoto, Asami Watanabe, Kumiko Yasui, Sachie Case Rep Endocrinol Case Report Humoral hypercalcemia of malignancy (HHM) is caused by the oversecretion of parathyroid hormone-related peptide (PTHrP) from malignant tumors. Although any tumor may cause HHM, that induced by intrahepatic cholangiocarcinoma (ICC) or gastric cancer (GC) is rare. We report here a 74-year-old male who displayed HHM with both ICC and GC and showed an elevated serum PTHrP level. Treatment of the hypercalcemia with saline, furosemide, elcatonin, and zoledronic acid corrected his serum calcium level and improved symptoms. Because treatment of ICC should precede that of GC, we chose chemotherapy with cisplatin (CDDP) and gemcitabine (GEM). Chemotherapy reduced the size of the ICC and decreased the serum PTHrP level. One year after diagnosis, the patient was alive in the face of a poor prognosis for an ICC that produced PTHrP. Immunohistochemical staining for PTHrP was positive for the ICC and negative for the GC, leading us to believe that the cause of the HHM was a PTHrP-secreting ICC. In conclusion, immunohistochemical staining for PTHrP may be useful in discovering the cause of HHM in the case of two cancers accompanied by an elevated serum PHTrP level. Chemotherapy with CDDP and GEM may be the most appropriate treatment for a PTHrP-secreting ICC. Hindawi 2017 2017-05-10 /pmc/articles/PMC5442343/ /pubmed/28573053 http://dx.doi.org/10.1155/2017/7012520 Text en Copyright © 2017 Katsushi Takeda et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Takeda, Katsushi Kimura, Ryosuke Nishigaki, Nobuhiro Sato, Shinya Okamoto, Asami Watanabe, Kumiko Yasui, Sachie Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer |
title | Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer |
title_full | Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer |
title_fullStr | Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer |
title_full_unstemmed | Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer |
title_short | Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer |
title_sort | humoral hypercalcemia of malignancy with a parathyroid hormone-related peptide-secreting intrahepatic cholangiocarcinoma accompanied by a gastric cancer |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442343/ https://www.ncbi.nlm.nih.gov/pubmed/28573053 http://dx.doi.org/10.1155/2017/7012520 |
work_keys_str_mv | AT takedakatsushi humoralhypercalcemiaofmalignancywithaparathyroidhormonerelatedpeptidesecretingintrahepaticcholangiocarcinomaaccompaniedbyagastriccancer AT kimuraryosuke humoralhypercalcemiaofmalignancywithaparathyroidhormonerelatedpeptidesecretingintrahepaticcholangiocarcinomaaccompaniedbyagastriccancer AT nishigakinobuhiro humoralhypercalcemiaofmalignancywithaparathyroidhormonerelatedpeptidesecretingintrahepaticcholangiocarcinomaaccompaniedbyagastriccancer AT satoshinya humoralhypercalcemiaofmalignancywithaparathyroidhormonerelatedpeptidesecretingintrahepaticcholangiocarcinomaaccompaniedbyagastriccancer AT okamotoasami humoralhypercalcemiaofmalignancywithaparathyroidhormonerelatedpeptidesecretingintrahepaticcholangiocarcinomaaccompaniedbyagastriccancer AT watanabekumiko humoralhypercalcemiaofmalignancywithaparathyroidhormonerelatedpeptidesecretingintrahepaticcholangiocarcinomaaccompaniedbyagastriccancer AT yasuisachie humoralhypercalcemiaofmalignancywithaparathyroidhormonerelatedpeptidesecretingintrahepaticcholangiocarcinomaaccompaniedbyagastriccancer |